about
Advances in the treatment of fragile X syndromeFragile x syndromeMolecular and cognitive predictors of the continuum of autistic behaviours in fragile XCytogenetic abnormalities and fragile-X syndrome in Autism Spectrum DisorderAdvances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum DisorderFragile X spectrum disordersUnstable mutations in the FMR1 gene and the phenotypesRepeat-mediated genetic and epigenetic changes at the FMR1 locus in the Fragile X-related disordersTherapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and BackA new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stabilityPhenobarbital use and neurological problems in FMR1 premutation carriersModeling fragile X syndrome in the Fmr1 knockout mouseFragile X: leading the way for targeted treatments in autism.Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome.The clinical-basic interface in defining pathogenesis in disorders of neurodevelopmental origin.Fragile X: a family of disorders.Joint Engagement and Early Language in Young Children With Fragile X SyndromeTask-switching deficits and repetitive behaviour in genetic neurodevelopmental disorders: data from children with Prader-Willi syndrome chromosome 15 q11-q13 deletion and boys with Fragile X syndrome.Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio.CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size.Broad clinical involvement in a family affected by the fragile X premutation.Open-label add-on treatment trial of minocycline in fragile X syndrome.Biomarkers in the Study of Families of Individuals with Developmental Disabilities.Aging in fragile X syndrome.iPSC-derived forebrain neurons from FXS individuals show defects in initial neurite outgrowthAutism spectrum disorder in children and adolescents with fragile X syndrome: within-syndrome differences and age-related changes.FMR1 intron 1 methylation predicts FMRP expression in blood of female carriers of expanded FMR1 alleles.Testing the FMR1 promoter for mosaicism in DNA methylation among CpG sites, strands, and cells in FMR1-expressing males with fragile X syndrome.High-risk fragile x screening in Guatemala: use of a new blood spot polymerase chain reaction techniqueFragile X and autism: Intertwined at the molecular level leading to targeted treatments.Clinical and molecular implications of mosaicism in FMR1 full mutations.Consistency between research and clinical diagnoses of autism among boys and girls with fragile X syndrome.Increasing our understanding of human cognition through the study of Fragile X Syndrome.Early intervention combined with targeted treatment promotes cognitive and behavioral improvements in young children with fragile x syndrome.Parent ratings of ability to consent for clinical trials in fragile X syndrome.Molecular Advances Leading to Treatment Implications for Fragile X Premutation CarriersPhonological awareness and reading in boys with fragile X syndromeClinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization.Negotiating desires and options: how mothers who carry the fragile X gene experience reproductive decisions.Longitudinal changes in intellectual development in children with Fragile X syndrome.
P2860
Q24632814-460CEB97-924B-449B-98B3-580A44C79F77Q24633000-49499BB7-630E-47D8-BCD7-D1D50E842B52Q24671887-18A702F3-29B7-4EE4-9B33-70509AF38F43Q24801230-9FC7F331-F756-4674-A8D6-E8C3793FBAABQ26781265-F4EC5CEF-8EF0-4F6C-AF1C-9E0BA16CA6B0Q26824376-820DE396-FDBE-4FCC-9995-C404CD276E28Q26996649-90A725B1-BB92-4905-9FAD-2FADF8F032E5Q27011565-C0B62AD7-A0CE-4681-9CDA-4654605B8A99Q27337360-5171E8E5-70BC-41D0-8643-B47E0F0B9621Q28116039-3F447265-AE4A-4D78-8185-B72ED292221FQ28390629-18788DCD-0B95-4D5E-9A78-EC26E6AD617CQ30420595-9C0B7D75-5AD6-4AE6-AE79-5E11326B814CQ30435321-BA549BCA-A260-40AE-927D-7C9721923D3BQ30441120-B438F4DE-A31F-4C7E-B457-F55F1DD10EC6Q30474180-A5010329-66EF-4B5A-B850-6FA59DE816C9Q30479991-411A27A7-867F-4720-9DCD-B3251DF7198CQ30841463-A29E7867-795D-41A6-8614-826D6B211CF5Q33409894-74690991-0370-4912-B53E-0BAB990E715FQ33527737-1AAF69E2-539F-46B8-9F4D-9585B6397203Q33649307-195FC555-938E-43E0-B601-6132401D0698Q33656457-D8FA2C68-4EEB-489A-BA6B-A07729F3D0CFQ33715073-FD09F4CC-525C-4CA5-A9BB-1D9477812455Q33795272-73BBE09A-3A22-458B-A4BB-AE4C522BCB4BQ33901217-9D2CDDEC-A634-46E2-95E2-37DC7C6D0140Q33919340-28649FCD-8F2C-45EE-9141-43A4A92199CFQ33921054-71599C9D-2C3F-48B5-87E8-6F6D15CFF1BFQ33949054-C9766A8F-7284-4D7F-9FFF-8B26F30F10FEQ34016335-3206EEB3-E61F-4087-B9E3-86DB2C3CFAF3Q34112106-DA9C5524-B19E-4228-912F-365D785E7A36Q34198650-20A724C4-F687-4735-9CD8-080F34D8D4C0Q34198878-463D9669-22CB-45B2-8528-981314CBA64AQ34395189-7F041773-3739-4D42-BE7B-3D7BAE0368F1Q34435526-C77D4A11-6152-41A8-8E89-266E722A2748Q34449331-ECA40123-F141-4DBA-ACF7-EB617303E444Q34557464-2EB2CC28-C583-4575-9DBC-776D90E5676FQ34575595-9A33226E-790F-42DF-9807-E6C6BE7DFE0CQ34627195-CEEF2567-08E0-4960-9A88-9CA1921889C2Q34669757-8F9FAAC0-F8C2-4D70-ABD5-5E77E26109EFQ34762304-4CCC1EA5-5F47-4D57-866C-D76BCA5702C1Q34762581-FCC51732-5162-405E-94AB-9D059196E8D3
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Phenotypic variation and FMRP levels in fragile X.
@ast
Phenotypic variation and FMRP levels in fragile X.
@en
type
label
Phenotypic variation and FMRP levels in fragile X.
@ast
Phenotypic variation and FMRP levels in fragile X.
@en
prefLabel
Phenotypic variation and FMRP levels in fragile X.
@ast
Phenotypic variation and FMRP levels in fragile X.
@en
P2093
P356
P1476
Phenotypic variation and FMRP levels in fragile X.
@en
P2093
Danuta Z Loesch
Randi J Hagerman
Richard M Huggins
P2860
P356
10.1002/MRDD.20006
P577
2004-01-01T00:00:00Z